Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT05868226

PRE-I-SPY Phase I/Ib Oncology Platform Program

Led by QuantumLeap Healthcare Collaborative · Updated on 2025-04-04

124

Participants Needed

7

Research Sites

358 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

I-SPY Phase I/Ib (I-SPY-P1) is an open-label, multisite platform study designed to evaluate single agents or combinations in a metastatic treatment setting that may be relevant for breast cancer patients with the overall goal of moving promising drug regimens into the I-SPY 2 SMART Design Trial (NCT01042379) and/or other oncology-based trials in a timely manner.

CONDITIONS

Official Title

PRE-I-SPY Phase I/Ib Oncology Platform Program

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Ability to understand and willing to provide written informed consent before study procedures
  • Age 18 years or older at informed consent signing
  • Male or female (pre- or postmenopausal)
  • Eastern Cooperative Oncology Group (ECOG) performance status grade 0-2
  • Estimated life expectancy greater than 12 weeks at treatment start
  • Adequate organ function confirmed by lab tests within 30 days before treatment start, including specific blood counts and liver and kidney function
  • Negative pregnancy test within 14 days before treatment start for women of childbearing potential; men must agree to avoid sperm donation during treatment
  • Willingness to use effective contraception during treatment
  • Resolution of acute toxic effects from prior therapy to grade 1 or less and neuropathy to grade 2 or less (except non-safety risk toxicities)
  • Willing and able to comply with study visits, treatment, and testing
  • Additional inclusion criteria may apply based on specific drug arm
Not Eligible

You will not qualify if you...

  • Recent anticancer therapy within specified washout periods (e.g., chemotherapy or investigational agents within 3 weeks)
  • Concurrent use of other investigational products
  • History of hypersensitivity or infusion reactions to study drugs leading to treatment discontinuation
  • Uncontrolled illnesses including active infection, recent pulmonary embolism, diabetes, or psychiatric/social issues limiting compliance
  • Significant cardiovascular disease within 6 months before treatment start
  • Active uncontrolled central nervous system cancer or spinal cord compression, except stable or asymptomatic lesions
  • Significant liver disease including viral hepatitis, alcohol abuse, or cirrhosis
  • Major surgery within 4 weeks before treatment start
  • Pregnancy or breastfeeding
  • Institutionalization due to legal or regulatory order
  • Other conditions compromising safety or study completion as judged by investigator
  • Diagnosis of another malignancy within 2 years prior to study treatment except indolent or treated malignancies
  • Additional exclusion criteria may apply based on specific drug arm

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

The University of Alabama at Birmingham O'Neal Comprehensive Cancer Center

Birmingham, Alabama, United States, 35233

Actively Recruiting

2

Moffitt Cancer Center

Tampa, Florida, United States, 33612

Actively Recruiting

3

The University of Chicago Medicine Comprehensive Cancer Center

Chicago, Illinois, United States, 60637

Actively Recruiting

4

UChicago Medicine Comprehensive Cancer Center at Silver Cross Hospital

New Lenox, Illinois, United States, 60451

Actively Recruiting

5

UChicago Medicine Orland Park

Orland Park, Illinois, United States, 60462

Actively Recruiting

6

University of Minnesota Masonic Cancer Center

Minneapolis, Minnesota, United States, 55455

Actively Recruiting

7

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

Loading map...

Research Team

S

Smita M Asare

CONTACT

M

Maria Pitsiouni, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

PRE-I-SPY Phase I/Ib Oncology Platform Program | DecenTrialz